Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 508 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Buffer Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Treatment of Moderate to Severe Lateral Canthal Lines

NCT04249687
View directory record Official record
Conditions
Lateral Canthal Lines
Interventions
botulinum toxin, Placebo
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
8
States / cities
Manhattan Beach, California • San Diego, California • Solana Beach, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 24, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Muscle Afferent Feedback Effects in Patients With Heart Failure

NCT01919918
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
Muscle Contraction with Metabolite Solution Administration
Drug
Lead sponsor
University of Utah
Other
Eligibility
20 Years to 79 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Oct 24, 2026, 9:38 AM EDT
Completed Phase 1Phase 2 Interventional

In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy

NCT01976585
View directory record Official record
Conditions
Low-Grade B-cell Lymphoma
Interventions
rhuFlt3L/CDX-301, Poly-ICLC
Drug
Lead sponsor
Joshua Brody
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 24, 2026, 9:38 AM EDT
Completed Phase 2 Interventional

Efficacy of NicVAX in Smokers Who Want to Quit Smoking

NCT00318383
View directory record Official record
Conditions
Smoking Cessation
Interventions
NicVAX conjugate vaccine, Placebo
Biological
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Farmington, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 24, 2026, 9:38 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

RHA® Redensity With New Anesthetic Agent Perioral Rhytids (PAS)

NCT06378086
View directory record Official record
Conditions
Pain, Aging
Interventions
RHA® Redensity with new anesthetic agent, RHA® Redensity with lidocaine
Device
Lead sponsor
Teoxane SA
Industry
Eligibility
22 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Birmingham, Alabama • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 24, 2026, 9:38 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

2013/2017 H7N9 Prime-Boost Interval

NCT03589807
View directory record Official record
Conditions
Avian Influenza, Influenza Immunisation
Interventions
A/H7N9, AS03, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, Phosphate Buffered Saline (PBS) diluent
Biological · Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 50 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
6
States / cities
Atlanta, Georgia • Decatur, Georgia • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 24, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of RO6806127 in Healthy Male Volunteers

NCT02196636
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Placebo, RO6806127
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 24, 2026, 9:38 AM EDT
Completed Not applicable Interventional Results available

TEOSYAL® RHA Ultra Deep and Perlane-L® for the Correction of Nasolabial Folds

NCT02253147
View directory record Official record
Conditions
Nasolabial Folds, Wrinkles
Interventions
TEOSYAL® RHA Ultra Deep
Device
Lead sponsor
Teoxane SA
Industry
Eligibility
22 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Beverly Hills, California • Bradenton, Florida • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 24, 2026, 9:38 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Inducing Self-Dehumanization to Examine Oxytocin and Suicide Risk

NCT06710964
View directory record Official record
Conditions
Mechanistic Self-Dehumanization Condition, Control Condition
Interventions
The Ten Item Personality Inventory, Mechanistic Self-Dehumanization Condition, Debrief, Control Condition, Clinical Interview, Self-Report Measures, Blood Draw
Other · Diagnostic Test
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 24, 2026, 9:38 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis

NCT02039687
View directory record Official record
Conditions
Neuropathy of Sarcoidosis
Interventions
ARA 290, Placebo
Drug · Other
Lead sponsor
Araim Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 24, 2026, 9:38 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

NCT01454063
View directory record Official record
Conditions
Intraocular Lens Replacement
Interventions
OMS302, Placebo
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
16
States / cities
Chandler, Arizona • Glendale, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 24, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5N1 Mix and Match With AS03

NCT01317758
View directory record Official record
Conditions
Influenza
Interventions
AS03 Adjuvant, Phosphate Buffered Saline (PBS) diluent, Sanofi H5N1 Antigen
Drug · Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
4
States / cities
Baltimore, Maryland • Nashville, Tennessee • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 24, 2026, 9:38 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome

NCT02996448
View directory record Official record
Conditions
Autosomal-dominant Hyper-IgE Syndrome
Interventions
NDV-3A
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 24, 2026, 9:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preventing Internalizing in Preadolescents Exposed to Chronic Stress

NCT02764138
View directory record Official record
Conditions
Chronic Stress, Anxiety, Depression
Interventions
Building a Strong Identity and Coping Skills
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
11 Years to 12 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Harrisburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 24, 2026, 9:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine

NCT00677820
View directory record Official record
Conditions
Influenza
Interventions
Trivalent influenza virus vaccine, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
Daytona Beach, Florida • Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2010 · Synced Oct 24, 2026, 9:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Local Anesthetics for Pain Reduction Prior to IV Line Placement

NCT01759459
View directory record Official record
Conditions
Pain, Local Anesthesia for Peripheral Intravenous Catheterization
Interventions
Lidocaine, Buffered Lidocaine, Bacteriostatic Normal Saline
Drug
Lead sponsor
Allina Health System
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 15, 2022 · Synced Oct 24, 2026, 9:38 AM EDT
Completed Phase 2 Interventional

An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis

NCT01273389
View directory record Official record
Conditions
Lupus Nephritis
Interventions
CNTO 136, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Oct 24, 2026, 9:38 AM EDT
Completed Not applicable Interventional

Improving Access to Community-Based Occupations Via a Rideshare Training Program

NCT06323850
View directory record Official record
Conditions
Autism
Interventions
Intervention Phase, Virtual Training Sessions, Ride-Along Training Sessions
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 24, 2026, 9:38 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

NCT01546142
View directory record Official record
Conditions
Moderate or Severe Submental Fullness
Interventions
Deoxycholic acid injection, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
516 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
30
States / cities
Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2015 · Synced Oct 24, 2026, 9:38 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study

NCT02316470
View directory record Official record
Conditions
Clostridium Difficile
Interventions
VLA84, Placebo
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
50 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
7
States / cities
Huntsville, Alabama • Chula Vista, California • La Mesa, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 24, 2026, 9:38 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis

NCT01746420
View directory record Official record
Conditions
Lateral Epicondylitis
Interventions
rhPDGF-BB Injection, Placebo
Drug
Lead sponsor
BioMimetic Therapeutics
Industry
Eligibility
21 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
6
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 24, 2026, 9:38 AM EDT
Withdrawn Phase 2 Interventional

Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

NCT01504542
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
HS110 vaccine, Placebo
Biological
Lead sponsor
Heat Biologics
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2013 · Synced Oct 24, 2026, 9:38 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Hypertonic Saline in Posterior Spinal Fusion

NCT06822374
View directory record Official record
Conditions
Scoliosis Idiopathic, Scoliosis;Congenital
Interventions
Normosol-R, buffered 2% hypertonic saline
Drug
Lead sponsor
Joseph D. Tobias
Other
Eligibility
10 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 24, 2026, 9:38 AM EDT
Terminated Early Phase 1 Interventional

Use of Tranexamic Acid in Reduction of Post-Op Complications in Mohs Micrographic Surgery

NCT04630886
View directory record Official record
Conditions
Skin Neoplasms
Interventions
Tranexamic acid injection, Lidocaine Epinephrine
Drug
Lead sponsor
Riley McLean
Other
Eligibility
18 Years to 99 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 24, 2026, 9:38 AM EDT